REVerse Intestinal Metaplasia in the Stomach (REVISE)

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Gastric Intestinal Metaplasia, Gastric Precancer

In brief

This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment. A secondary aim will be to generate gastric organoids from patient-derived samples to test the effects of pyrvinium in vitro in patient-derived samples, and also to identify new drugs that may help reverse gastric intestinal metaplasia.

Key facts

Study ID

NCT06590454

Run by

Katherine Garman

People needed

32

Starts

2025-12-15

Expected to finish

2026-10-01

Last updated by the study team

2026-02-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (including men, women, and non-binary individuals) over age 18 with known GIM with at least one high-risk feature (extensive vs limited, incomplete or mixed-type GIM, family history of stomach cancer),
• Ability to provide informed consent,
• Evidence of prior but not active H. pylori infection

You may not qualify if…

• Active gastric cancer diagnosis,
• High-risk of bleeding complications due to anticoagulants or underlying medical condition,
• Pregnancy (which is a contraindication to non-emergent endoscopy due to anesthesia risks)

Where it is running

• Duke Health — Durham, North Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.